Lung Therapeutics has concluded the Phase Ia clinical trial of its Caveolin-1-related peptide, LTI-03, intended for the treatment of idiopathic pulmonary fibrosis (IPF).

A seven amino acid peptide, LTI-03, addresses hindrance of pro-fibrotic signalling and key epithelial cell survival.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The company noted that LTI-03 is a dry powder formulation intended for direct-to-lung administration.

The trial evaluated ascending doses of LTI-03 in healthy subjects. 

According to the findings from the trial, dose levels ranging from 2.5mg to 10mg of LTI-03 were demonstrated to be safe and well-tolerated.

Furthermore, no study discontinuations or serious adverse events were reported in this trial. 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Lung Therapeutics president and CEO Brian Windsor said: “We are pleased that LTI-03 has passed this important safety milestone as we continue development. 

“We believe that the mechanism LTI-03 is unique among drugs in development for IPF, and we are excited to move LTI-03 into the next stage of clinical development in IPF patients later this year.”

The company noted that LTI-03 performed well at dose levels equivalent to a human dose ranging from 1 to 10mg in preclinical animal and ex-vivo models.

In addition, these preclinical data showed that the treatment with LTI-03 hindered pro-fibrotic signalling and preserved critical alveolar epithelial type 2 (AEC2) cells in the lungs.

Lung Therapeutics and Taiho Pharmaceutical signed an exclusive license agreement in November 2020 for a recombinant human single-chain urokinase plasminogen activator, LTI-01, in Japan.

In March 2017, the company commenced subject enrolment and dosing in a Phase Ia/b trial of LTI-01 to treat patients with loculated pleural effusions in Australia and New Zealand.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact